An Open-Label, Single-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Injection in Heart Failure Patients on Standard Therapy

Trial Profile

An Open-Label, Single-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Injection in Heart Failure Patients on Standard Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2013

At a glance

  • Drugs Recombinant human neuregulin 1-beta (Primary)
  • Indications Chronic heart failure
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 24 May 2013 Results published.
    • 24 May 2013 New trial record
    • 23 May 2013 Pooled phase II results published in a Zensun Sci & Tech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top